Amgen NASDAQ:AMGN, the biotech heavyweight behind treatments for cancer, cardiovascular disease and other serious illnesses, gave investors another reason to cheer after posting a stronger-than-expected second quarter. Reuters reported revenue climbed 9% year over year to about $10.05 billion, whil…
What Happened? Shares of biotech company Amgen NASDAQ:AMGNjumped 3.1% in the afternoon session after the company reported strong second-quarter 2026 financial results that beat expectations and prompted it to raise its full-year guidance.Total revenue for the quarter increased 9.5% year-over-year t…
Amgen Inc reported second-quarter 2026 results with revenue of $10.05B and diluted EPS of $4.37, versus $9.18B and $2.65 in the year-ago quarter, driven by product sales growth and stronger demand for several key medicines.Financial Highlights¹ Reported as “Total revenues”. ² Reported as “Net incom…
Pfizer, Merck and Amgen outlined plans to expand their cancer portfolios as part of their earnings on Tuesday, fueling more speculative retail chatter around smaller oncology companies like Sellas Life Sciences (SLS) and ImmunityBio (IBRX).Pfizer Targets Cancer Growth With PadcevPfizer called oncol…
Q2 2026 revenues rose 10% year-over-year to over $10 billion, driven by strong growth across six key product areas, with 22 products posting double-digit sales gains. Guidance for 2026 was raised, reflecting robust pipeline progress and continued investment in innovation.Based on Amgen Inc. [AMGN…
Six key growth drivers fueled 26% YoY growth, contributing nearly 70% of Q2 sales. Total revenues rose 10% to $10.1B, with strong performance in rare disease, oncology, and biosimilars. 2026 guidance was raised for both revenue and EPS, reflecting confidence in continued momentum.Original document…
Q2 2026 revenues rose 10% year-over-year to $10.1B, with strong growth in key products and pipeline progress. GAAP EPS surged 65% to $4.37, while non-GAAP EPS rose 4% to $6.29. Full-year guidance projects continued revenue and EPS growth.Original document: Amgen Inc. [AMGN] SEC 8-K Current Report —…
Two-Year Commitment will Inspire the Next Generation of Scientific Innovators Through AI-Enabled Research in Healthcare and Drug DiscoveryHYDERABAD, India, July 31, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of the first Amgen Scholars Program in India at the International…
Bristol Myers Squibb NYSE:BMY, a drugmaker focused on creating new medicines, is expanding its three-year partnership with Nvidia, a chipmaker providing artificial intelligence computing technology, to increase the power of its AI factory. Bristol Myers said the system is being used to develop medi…
Vertex Pharmaceuticals NASDAQ:VRTX has agreed to buy Crinetics Pharmaceuticals NASDAQ:CRNX for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical…
Amgen Price Target Maintained With a $350.00/Share by Cantor Fitzgerald
Explore more price target data and ratings for Amgen Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Amgen Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a rec…
Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KRAS G12C non-small cell lung cancer (NSCLC).Divarasib is an investigational, next-generation, oral, KRAS G12C inhibitor. This phase III, ran…
What Happened? Shares of biotech company Amgen NASDAQ:AMGNjumped 3.1% in the afternoon session after the company received a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug, Enbrel.A federal judge in Colorado granted a preliminary injunction, halting t…
By Jonathan StempelA federal judge on Wednesday blocked Colorado from capping the price of Amgen's NASDAQ:AMGN blockbuster arthritis drug Enbrel, a first-of-its-kind move by a U.S. state.In granting a preliminary injunction, Chief Judge Daniel Domenico of the Denver federal court said Amgen would l…
Amgen NASDAQ:AMGN is facing fresh pressure after the New England Journal of Medicine retracted the 2021 clinical trial used to support approval of Tavneos, its pill for ANCA-associated vasculitis. The journal said two study authors requested the retraction after an FDA investigation found results f…
By Puyaan SinghThe New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s NASDAQ:AMGN rare-disease drug, citing concerns that patient outcome data were altered and that some researchers had been unblinded.The journal said two ac…
The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s NASDAQ:AMGN rare-disease drug, citing concerns that patient outcome data were altered and that some researchers had been unblinded.The journal said two academic authors…
By Siddhi MahatoleThe U.S. Food and Drug Administration has approved Viridian Therapeutics' NASDAQ:VRDN drug to treat patients with thyroid eye disease, the company said on Friday, sending its shares up 6% in extended trading.The decision gives patients a new treatment option in a market where Amge…
The U.S. Food and Drug Administration declined to approve Swedish drugmaker Sobi's OMXSTO:SOBI therapy to treat uncontrolled gout, a common form of inflammatory arthritis, the company said on Friday.In its so-called complete response letter, the FDA asked the company to provide more data, mainly re…
